Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster discussion - Basic science

5774 - A joint metabolic profile of plasma and tissue samples for discovering novel biomarkers in breast cancer


22 Oct 2018


Poster discussion - Basic science


Translational Research

Tumour Site

Breast Cancer


Narumi Harada


Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304


N. Harada, H. Tada, M. Miyashita, Y. Hamanaka, A. Sato, T. Ishida

Author affiliations

  • Department Of Breast And Endocrine Surgical oncology, Tohoku University Hospital, 980-8575 - Sendai/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5774


The dysregulated tumour metabolism is one of the hallmarks of cancer. Metabolome analysis has thus been proposed as a broadly applicable tool for diagnosis and anti-cancer treatment in various cancers, such as lung, colorectal and breast cancers. Up until now, a number of metabolic biomarkers have been reported; however, there is still little application in a clinical setting due to the fact that the metabolic approach with the clinical samples has not been generally authorized. In this study, using metabolome analysis, we determined the cancer-specific metabolites and explored the applicability of the liquid biopsy for discovering the potential biomarkers of breast cancer.


A total of 22 patients with breast cancer were enrolled and their metabolite levels were analyzed with CE-MS, quantitating 511 identifiable metabolites in plasma and non-cancer/cancer tissues. Samples were immediately kept in liquid nitrogen and stored at -80˚C until further tissue processing, including removal of proteins prior to CE-MS analysis. All the available metabolite data with absolute concentration were analyzed using a web-based platform, MetaboAnalyst 4.0.


A total of 511 known metabolites were measured; of these, 159 metabolite changes in concentration were observed in cancer tissues compared with in non-cancer tissues. In plasma samples, 67/159 metabolites significantly increased in cancer tissues. The affected metabolites were 2-hydroxyglutarate, succinate and fumarate, all of which are known as representative "oncometabolites" involved in tumorigenesis. Moreover, metabolites associated with purine synthesis and pyrimidine synthesis were also markedly upregulated. These cancer-related metabolic changes had correlation with the proliferation markers of cancer tissues.


We identified for the first time the signature of metabolic reprograming between non-cancer and cancer tissues in breast cancer, and this metabolic shift was observed in plasma. The plasma levels of biomarkers relating to nucleic acid synthesis (purine and pyrimidine synthesis) was associated with the high proliferation status of breast cancer.

Clinical trial identification

Legal entity responsible for the study

Narumi Harada.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.